建信纳斯达克100指数型证券投资基金(QDII)
Search documents
公告速递:建信纳斯达克100指数(QDII)基金基金暂停申购、定期定额投资
Sou Hu Cai Jing· 2025-11-18 20:16
证券之星消息,11月18日建信基金管理有限责任公司发布《建信纳斯达克100指数型证券投资基金 (QDII)基金暂停申购、定期定额投资公告》。公告中提示,为保护投资者利益,自2025年11月19日 起建信纳斯达克100指数型证券投资基金(QDII)基金暂停申购、定期定额投资,下属分级基金调整明 细如下: | 分级基金简称 | 代码 | 是否暂停(大额)申购 | 申购限额 | 转入限额 | 定投限额 | | --- | --- | --- | --- | --- | --- | | | | (转入转出、赎回、定投) | (元) | (元) | (元) | | 建信纳斯达克100指数 QDII) A美元现汇 | 012751 | 를 | | | | | 建信纳斯达克100指数( QDII) A人民币 | 539001 | 를 | | | | | 建信纳斯达克100指数 QDII)C美元现汇 | 012753 | 를 | | | | | 建信纳斯达克100指数 ( QDII) C人民币 | 012752 | 를 | | | | | 建信纳斯达克100指数( QDII) D人民币 | 023422 | 를 | | | ...
建信现金增利货币市场基金B类基金份额在中国建设银行销售渠道暂停大额申购、大额转换转入、定期定额投资公告
Zhong Guo Zheng Quan Bao - Zhong Zheng Wang· 2025-09-27 00:43
Group 1 - The announcement states that the B-class shares of the Jianxin Cash Growth Money Market Fund will suspend large subscriptions, large conversions, and regular fixed investments through the China Construction Bank sales channel starting from September 29, 2025 [1][3] - During the suspension period, the total amount of subscriptions, conversions, and fixed investments for a single fund account on a single day should not exceed 200 million yuan, and exceeding this limit may result in the rejection of the related transactions [1][3] - Investors can contact the fund management company's customer service hotline for inquiries or visit the official website for more information [1][3] Group 2 - The Jianxin Nasdaq 100 Index Securities Investment Fund (QDII) will also suspend large subscriptions and regular fixed investments starting from September 29, 2025, with specific limits set for both RMB and USD shares [4][5] - For RMB shares, the limit for a single fund account on a single day is set at 5,000 yuan, while for USD shares, the limit is 700 USD [4][5] - The specific date for the resumption of large subscriptions and fixed investment business will be announced later [5] Group 3 - Jianxin Fund Management Company has participated in the non-public issuance of A-shares by Sichuan Baili Tianheng Pharmaceutical Co., Ltd. (688506) [7] - The announcement includes details regarding the allocation of A-shares to the funds managed by the company, in compliance with relevant regulations [7]